BSD Medical Announces News Coverage Highlights Value of Hyperthermia for Breast Cancer Patients

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corp. (NASDAQ:BSDM) today reported that hyperthermia treatment delivered at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas was highlighted in a television segment titled, “Turning up the heat on breast cancer,” which aired on WFAA-TV, a Dallas/Fort Worth ABC affiliated television station. The story can be viewed at: http://www.kvue.com/home/Turning-up-the-heat-on-breast-cancer-108427529.html. The segment highlights the value of hyperthermia for the treatment of breast cancer patients who have failed other therapies. The treatment reported in the segment utilized the BSD-500 Hyperthermia System to deliver the hyperthermia.

Barry N. Wilcox, MD, Chief of Radiation Oncology at Baylor University Medical Center, was quoted on his experience regarding hyperthermia. Dr. Wilcox stated, "The data is trickling in, and I'm sure this will be more widespread in the future."

About Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and provides advanced treatment and therapy options to help patients in their fight against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with more than 300 physicians serving 100 sites of service throughout Texas and Southeastern New Mexico. Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Through its affiliation with US Oncology and the US Oncology Research network, Texas Oncology participates in innovative clinical trials from Phase I through Phase IV, and has played a role in the development of 42 Food and Drug Administration (FDA) approved cancer therapies.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.



CONTACT:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
[email protected]

KEYWORDS:   United States  North America  Texas  Utah

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology  Radiology  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.